Nasus Pharma (NSRX) Company presentation summary

Strategic positioning and technology

• Proprietary Nasax powder technology enhances intranasal drug absorption, targeting rapid and precise delivery for emergency conditions.

• Lead product NS002 offers a needle-free, easy-to-administer alternative to injectable epinephrine, addressing limitations of autoinjectors.

• Platform uses well-known APIs, enabling a lower-risk 505(b)(2) regulatory pathway.

• Nasax powder formulation provides longer shelf-life and robust IP protection through 2038-2045.

• Strong financial position supports pivotal studies and pipeline development.

Clinical pipeline and development milestones

• NS002 (intranasal epinephrine) has completed Phase 2 studies, showing faster and higher absorption than EpiPen®.

• NS001 (intranasal naloxone) completed pivotal Phase 3, demonstrating faster delivery and higher absorption than Narcan®.

• Additional candidates include NS003 (ondansetron for nausea/vomiting), NS004 (metabolic), and NS005 (cardiovascular), all in preclinical stages.

• Pivotal trial for NS002 expected to initiate Q4 2026, with NDA submission planned for H2 2027.

Market opportunity and competitive landscape

• Anaphylaxis affects 1–3% globally, with a $2.3B epinephrine market and significant unmet need for needle-free solutions.

• NS002 targets patients who avoid autoinjectors due to needle fear or inconvenience, aiming to improve adherence.

• Competitive PK data show NS002 achieves therapeutic plasma levels faster than EpiPen® and other intranasal or sublingual candidates.

• Surveyed allergists overwhelmingly value speed of onset, favoring products like NS002 with rapid absorption.